Evidence map›Paper›PMID 32303241›Full record

ArticleOrphanet journal of rare diseases2020

The French paediatric cohort of Castleman disease: a retrospective report of 23 patients.

Charlotte Borocco, Claire Ballot-Schmit, Oanez Ackermann, Nathalie Aladjidi, Jeremie Delaleu, Vannina Giacobbi-Milet, Sarah Jannier, Eric Jeziorski, François Maurier, Yves Perel and 4 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Candidate biomarkers for idiopathic multicentric Castleman disease.Journal of clinical and experimental hematopathology : JCEH · 2022
    Article
  11. Article
  12. Castleman disease.Nature reviews. Disease primers · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Charlotte BoroccoDepartment of Paediatric Rheumatology, CeReMAIA, CHU Bicêtre, Assistance Publique - Hôpitaux de Paris, Université Paris-Sud-Saclay, 94270, Le Kremlin Bicêtre, France.ORCID 0000-0002-2310-7930
Claire Ballot-SchmitDepartment of Paediatrics, CHU Jean Minjoz, Besançon, France.
Oanez AckermannDepartment of Paediatric Hepatology, CHU Bicêtre, Assistance Publique -Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Nathalie AladjidiPaediatric Oncology Haematology Unit, Hôpital Pellegrin, Bordeaux, France.
Jeremie DelaleuDepartment of Internal Medicine, CeReMAIA, CHU Tenon, Assistance Publique - Hôpitaux de Paris, Paris, France.
Vannina Giacobbi-MiletDepartment of Paediatric Haematology and Oncology, Centre Hospitalier du Mans, Le Mans, France.
Sarah JannierDepartment of Paediatric Haematology and Oncology, CHU Hautepierre, Strasbourg, France.
Eric JeziorskiDepartment of Paediatrics, CeReMAIA, CHU Arnaud de Villeneuve, Montpellier, France.
François MaurierDepartment of Internal Medicine, Hôpitaux privés de Metz, Metz, France.
Yves PerelPaediatric Oncology Haematology Unit, Hôpital Pellegrin, Bordeaux, France.
Christophe PiguetPaediatric Oncology Haematology Unit, CHU de Limoges, Limoges, France.
Eric OksenhendlerDepartment of Clinical Immunology, CHU Saint-Louis, Paris, France.
Isabelle Koné-PautDepartment of Paediatric Rheumatology, CeReMAIA, CHU Bicêtre, Assistance Publique - Hôpitaux de Paris, Université Paris-Sud-Saclay, 94270, Le Kremlin Bicêtre, France.
Caroline GaleottiDepartment of Paediatric Rheumatology, CeReMAIA, CHU Bicêtre, Assistance Publique - Hôpitaux de Paris, Université Paris-Sud-Saclay, 94270, Le Kremlin Bicêtre, France. caroline.galeotti@gmail.com.
Université Paris-Sud · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Pellegrin · FRCentre de Référence des Maladies Autoinflammatoires et des Amyloses · FRCentre Hospitalier du Mans · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Limoges · FRHôpital d'Hautepierre · FRHôpital Saint-Louis · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCastleman disease (CD) is a rare non-malignant lymphoproliferation of undetermined origin. Two major disease phenotypes can be distinguished: unicentric CD (UCD) and multicentric CD (MCD). Diagnosis confirmation is based on histopathological findings in a lymph node. We attempted to survey all cases of paediatric CD identified to date in France to set up a national registry aiming to improve CD early recognition, treatment and follow-up, within the context of a new national reference center (http://www.castleman.fr).

methodsIn 2016, we e-mailed a questionnaire to members of the French paediatric immunohaematology society, the paediatric rheumatology society and the Reference Centre for Castleman Disease to retrospectively collect cases of paediatric CD (first symptoms before age 18 years). Anatomopathological confirmation was mandatory.

resultsWe identified 23 patients (12 girls) with a diagnosis of UCD (n = 17) and MCD (n = 6) between 1994 and 2018. The mean age at first symptoms was 11.47 ± 4.23 years for UCD and 8.3 ± 3.4 years for MCD. The mean diagnosis delay was 8.16 ± 10.32 months for UCD and 5.16 ± 5.81 years for MCD. In UCD, the initial symptoms were isolated lymph nodes (n = 10) or lymph node associated with other symptoms (n = 7); fever was present in 3 patients. Five patients with MCD presented fever. No patients had HIV or human herpesvirus 8 infection. Autoinflammatory gene mutations were investigated in five patients. One patient with MCD carried a K695R heterozygous mutation in MEFV, another patient with MCD and Duchenne myopathy carried two variants in TNFRSF1A and one patient with UCD and fever episodes carried two heterozygous mutations, in IL10RA and IL36RN, respectively. Treatment of UCD was mainly surgical resection, steroids, and radiotherapy. Treatment of MCD included tocilizumab, rituximab, anakinra, steroids, chemotherapy, and splenectomy. Overall survival after a mean of 6.1 ± 6.4 years of follow-up, was 100% for both forms.

conclusionPaediatric CD still seems underdiagnosed, with a significant diagnosis delay, especially for MCD, but new international criteria will help in the future. Unlike adult CD, which is strongly associated with HIV and human herpesvirus 8 infection, paediatric CD could be favored by primary activation of innate immunity and may affect life expectancy less.

Indexed as

Castleman DiseaseAdolescentAdultChildFemaleFranceHumansInterleukinsLymph NodesPyrinRetrospective StudiesRituximabIL36RN protein, humanInterleukinsMEFV protein, humanPyrinRituximabMulticentricPaediatric Castleman diseaseTocilizumabUnicentric

Identifiers

PMID32303241
PMCPMC7164260
OpenAlexW3016503434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.